Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines. Issue 2 (2nd February 2016)

• Record Type: Journal Article
• Authors: Lin, Zu‐Yau; Kuo, Chao‐Hung; Wu, Deng‐Chyang; Chuang, Wan‐Long
• Is Part Of: Kaohsiung journal of medical sciences. Volume 32:Issue 2(2016)
• Page Start: 68
• Page End: 73
• Publication Date: 2016-02-02
• Subjects: Animal study -- Colchicine -- Gastric cancer -- Proliferation; Medicine -- Periodicals; 610.5
• DOI: 10.1016/j.kjms.2015.12.006
• Languages: English
• ISSNs: 1607-551X

Abstract

Abstract: Colchicine is a very cheap microtubule destabilizer. Because microtubules are an ideal target for anticancer drugs, the purpose of this study was to investigate whether clinically acceptable colchicine concentrations have anticancer effects on gastric cancer cells, and its possible anticancer mechanisms. Two human gastric cancer cell lines (i.e., AGS and NCI‐N87) were investigated by proliferative assay, microarray, quantitative reverse transcriptase‐polymerase chain reaction, and a nude mice study using clinically acceptable colchicine concentrations (2 ng/mL and 6 ng/mL for in vitro tests and 0.07 mg colchicine/kg/d for in vivo tests). Our results showed that colchicine had the same inhibitory effects on the proliferation of both cell lines. The antiproliferative effects of colchicine on both cell lines were achieved only at the concentration of 6 ng/mL ( p < 0.0001). In both cell lines, 18 genes were consistently upregulated and 10 genes were consistently downregulated by 6 ng/mL colchicine, compared with 2 ng/mL colchicine. Among these genes, only the upregulated DUSP1 gene may contribute to the antiproliferative effects of colchicine on gastric cancer cells. The nude mice (BALB/c‐nu) experiment showed that colchicine‐treated mice after 14 days of treatment had lower increased tumor volume ratios ( p = 0.0199) and tumor growth rates ( p = 0.024) than the control mice. In conclusion, colchicine has potential for the palliative treatment of gastric cancer. However, the anticancer effects are achieved only at high clinically acceptable colchicine concentrations. Monitoring the colchicine plasma concentration is mandatory if this drug is applied for the palliative treatment of gastric cancer.